Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 7, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The study is the first placebo-controlled trial to include non-ambulant adults with spinal muscular atrophy type 2 or 3.
The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.
Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.
Comparing accuracy of ultrasound-guided vs anatomical localization of botulinum toxic injections into cadaver salivary glands.
Recently published data showed that one-quarter of the smartphone videos were correctly diagnosed by 100% of the reviewing physicians.